Literature DB >> 28301317

Challenges in the analysis of epigenetic biomarkers in clinical samples.

José Luis García-Giménez1, Salvador Mena-Mollá1, Jesús Beltrán-García1, Fabian Sanchis-Gomar1.   

Abstract

Epigenetic modifications represent an interesting landscape which can describe relevant features of human disease. Epigenetic biomarkers show several advantages as disease biomarkers because they provide information about gene function, specific endophenotypes and can even incorporate information from the environment and the natural history of disease. The improvement in genomic and epigenomic technologies has revolutionized the current comprehension of biological processes underlying health and disease. However, now is the time to adopt these new technologies to improve human health, thus converting this information into reliable biomarkers. This endeavor should be focused on improving methodologies to analyze gene methylation, histone modifications and microRNAs. Ideally, epigenetic biomarkers should be robust, routine, accurate and inexpensive in order to provide better information for patient diagnosis, prognosis, stratification and treatment monitoring. Here we describe some challenges and provide strategies to improve the adoption of epigenetic biomarkers into clinical routine. Furthermore, we summarize the recommended properties for clinical epigenetic biomarkers.

Entities:  

Keywords:  ChIP assay; DNA methylation; formalin-fixed paraffin-embedded (FFPE); liquid biopsy; microRNAs (miRNAs)

Mesh:

Substances:

Year:  2017        PMID: 28301317     DOI: 10.1515/cclm-2016-1162

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  10 in total

1.  Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral rebound.

Authors:  Michael J Corley; Alina P S Pang; Thomas A Rasmussen; Martin Tolstrup; Ole S Søgaard; Lishomwa C Ndhlovu
Journal:  AIDS       Date:  2021-11-15       Impact factor: 4.177

2.  Hypomethylation status of miR-657 promoter region as biomarker for diagnosis of hepatocellular carcinoma: a retrospective study.

Authors:  Zhaoqi Shi; Peng Luo; Xiaoxiao Fan; Junhai Pan; Lifeng He; Daizhan Zhou; Hui Lin
Journal:  Transl Cancer Res       Date:  2022-05       Impact factor: 0.496

Review 3.  Clinical Parameters and Epigenetic Biomarkers of Plaque Vulnerability in Patients with Carotid Stenosis.

Authors:  Laia Carballo-Perich; Dolors Puigoriol-Illamola; Saima Bashir; Mikel Terceño; Yolanda Silva; Carme Gubern-Mérida; Joaquín Serena
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

Review 4.  Epigenetic Mechanisms of Epidermal Differentiation.

Authors:  Chiara Moltrasio; Maurizio Romagnuolo; Angelo Valerio Marzano
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

Review 5.  MiRroring the Multiple Potentials of MicroRNAs in Acute Myocardial Infarction.

Authors:  Solenne Paiva; Onnik Agbulut
Journal:  Front Cardiovasc Med       Date:  2017-11-20

Review 6.  Circular RNAs in Sepsis: Biogenesis, Function, and Clinical Significance.

Authors:  Jesús Beltrán-García; Rebeca Osca-Verdegal; Elena Nacher-Sendra; Federico V Pallardó; José Luis García-Giménez
Journal:  Cells       Date:  2020-06-25       Impact factor: 6.600

Review 7.  Epigenetic Biomarkers in Cardiovascular Diseases.

Authors:  Carolina Soler-Botija; Carolina Gálvez-Montón; Antoni Bayés-Genís
Journal:  Front Genet       Date:  2019-10-09       Impact factor: 4.599

Review 8.  The Challenge and Opportunity to Diagnose Parkinson's Disease in Midlife.

Authors:  Alexander Kilzheimer; Thomas Hentrich; Simone Burkhardt; Julia M Schulze-Hentrich
Journal:  Front Neurol       Date:  2019-12-17       Impact factor: 4.003

9.  Consistency of the S5 DNA methylation classifier in formalin-fixed biopsies versus corresponding exfoliated cells for the detection of pre-cancerous cervical lesions.

Authors:  Caroline Reuter; Matthew Preece; Rawinder Banwait; Sabrina Boer; Jack Cuzick; Attila Lorincz; Belinda Nedjai
Journal:  Cancer Med       Date:  2021-03-12       Impact factor: 4.452

Review 10.  DNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment?

Authors:  Gregory Alexander Raciti; Antonella Desiderio; Michele Longo; Alessia Leone; Federica Zatterale; Immacolata Prevenzano; Claudia Miele; Raffaele Napoli; Francesco Beguinot
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.